The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
Open accessAbstract
Introduction: Recent studies have identified subtypes of small cell lung carcinoma (SCLC) defined by RNA expression of ASCL1, NEUROD1, POU2F3 and YAP1 transcriptional regulators. There are only limited data on distribution of these markers at the protein level and associated pathologic characteristics in clinical SCLC samples. Methods: Expression of ASCL1, NEUROD1, POU2F3 and YAP1 was analyzed by immunohistochemistry in 174 SCLC patient samples. Subtypes defined by these markers were correlated with histologic characteristics, expression of neuroendocrine markers (synaptophysin, chromogranin A, CD56, INSM1) and other SCLC markers including neuroendocrine phenotype-associated marker DLL3. Results: ASCL1 and NEUROD1 expression had the following distribution: ASCL1+/NEUROD1− 41%, ASCL1+/NEUROD1+ 37%, ASCL1−/NEUROD1+ 8% and ASCL1−/NEUROD1− 14%. Based on the relative expression, 69% of cases were ASCL1-dominant and 17% NEUROD1-dominant. POU2F3 was expressed in 7% of SCLC, and was mutually exclusive of ASCL1 and NEUROD1. YAP1 was expressed at low levels, primarily in combined SCLC, and was not exclusive of other subtypes. Both ASCL1-dominant and NEUROD1-dominant subtypes were associated with neuroendocrine markerhigh/DLL3high profile, whereas POU2F3 and other ASCL1/NEUROD1-double-negative tumors were neuroendocrine markerlow/DLL3low. Conclusions: This is the first comprehensive immunohistochemical and histopathologic analysis of novel SCLC subtypes in patient samples. We confirm that ASCL1/NEUROD1-double-negative tumors represent a distinct neuroendocrine-low subtype of SCLC which is either uniquely associated with POU2F3 or lacks a known dominant regulator. Expression profiles of these markers appear more heterogeneous in native samples than in experimental models, particularly in regard to high prevalence of ASCL1/NEUROD1 co-expression. These findings may have prognostic and therapeutic implications and warrant further clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Self-citationTravis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000663 · Cited by 1,905
Self-citationWHO classification of tumours of the lung, pleura, thymus and heart
Travis, W. D. (2015) · International Agency for Research on Cancer eBooks · Cited by 1,664
Self-citationIntegrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationTuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit
von Moltke, J., Ji, M., Liang, H.-E., & Locksley, R. M. (2016) · Nature · doi:10.1038/nature16161 · Cited by 1,230
McCarty, K. S., MILLER, L. S., Cox, E. B., Konrath, J. G., & McCarty, K. S. (1985) · PubMed · Cited by 1,027
Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites
Gerbe, F., Sidot, E., Smyth, D. J., Ohmoto, M., Matsumoto, I., Dardalhon, V., Cesses, P., Garnier, L., Pouzolles, M., Brulin, B., et al. (2016) · Nature · doi:10.1038/nature16527 · Cited by 961
Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut
Howitt, M. R., Lavoie, S., Michaud, M., Blum, A. M., Tran, S. V., Weinstock, J. V., Gallini, C. A., Redding, K., Margolskee, R. F., Osborne, L. C., et al. (2016) · Science · doi:10.1126/science.aaf1648 · Cited by 928
Fedchenko, N., & Reifenrath, J. (2014) · Diagnostic Pathology · doi:10.1186/s13000-014-0221-9 · Cited by 808
Cited by
Gay, C. M., Stewart, C. A., Park, E. M., Diao, L., Groves, S. M., Heeke, S., Nabet, B. Y., Fujimoto, J., Solis, L. M., Lu, W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.014 · Cited by 962
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Wen, X., Pu, H., Liu, Q., Guo, Z., & Luo, D. (2022) · Cancers · doi:10.3390/cancers14246025 · Cited by 99
Metadata
- Authors
- Baine, M. K., Hsieh, M.-S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., Beras, A., Spencer, R., Lopardo, J., Bodd, F., Montecalvo, J., Sauter, J. L., Chang, J. C., Buonocore, D. J., Travis, W. D., Sen, T., Poirier, J. T., Rudin, C. M., & Rekhtman, N.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 15
- Issue
- 12
- Pages
- 1823-1835
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3090613431
- Cited by
- 522
- References
- 43
- FWCI
- 17.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. https://app.cochat.ai/papers/10.1016/j.jtho.2020.09.009
- The paper
- Baine, M. K., Hsieh, M.-S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., Beras, A., Spencer, R., Lopardo, J., Bodd, F., Montecalvo, J., Sauter, J. L., Chang, J. C., Buonocore, D. J., Travis, W. D., Sen, T., Poirier, J. T., Rudin, C. M., & Rekhtman, N. (2020). SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2020.09.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
